If you look into Johnson and Johnson (IONSYS), they are also dedicating huge resources into the delvelopment of Iontophoresis technolgy. Iontophoresis technology is a clincally proven method of reducing pain and swelling in the ohysical therapy marketplace through Iontophoretic electrodes. This transdermal delivery will also be vertically integrating in many other areas for its clinical bnefits outway injections of many types of commonly delivered drugs...I agree PATH is definatley way under valued here....
7:35AM NuPathe reports smaller-than-expected Q4 net loss (PATH) 4.50 : NuPathe reports Q4 EPS of ($0.38) vs ($0.49) Capital IQ Consensus Estimate; the co continues to believe it will be able to address all of the questions raised in the CRL for its migraine patch (NP101) in a timely fashion. NuPathe remains on track to resubmit its NDA in 1H12 and expects the resubmission will result in a six-month review by the Agency.
Market Data 
Markets 
AI
